Minocycline
- Generic Name
- Minocycline
- Brand Names
- Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N3O7
- CAS Number
- 10118-90-8
- Unique Ingredient Identifier
- FYY3R43WGO
- Background
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Minocycline was granted FDA approval on 30 June 1971.
- Indication
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Chlamydia trachomatis, Ureaplasma urealyticum, Borrelia recurrentis, Haemophilus ducreyi, Yersinia pestis, Francisella tularensis, Vibrio cholerae, Campylobacter fetus, Brucella species, Bartonella bacilliformis, Klebsiella granulomatis, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae, and Kelbsiella species.
- Associated Conditions
- Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
- Conditions
- Helicobacter Pylori Eradication
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 339
- Registration Number
- NCT04558502
Neuroinflammation in Hypertension Study
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Royal Perth Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04478500
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
Evaluate the Efficacy and Safety of Intense Pulsed Light Filters Combined With Oral Medication in the Treatment of Acne
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Gang Wang
- Target Recruit Count
- 60
- Registration Number
- NCT04433143
- Locations
- 🇨🇳
Dermatology Derpartment of Xijing Hospital, Xi'an, Shaanxi, China
Minocycline in MS: Confirmation of Benefit
- Conditions
- Clinically Isolated SyndromeMultiple Sclerosis
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 9
- Registration Number
- NCT04291456
- Locations
- 🇨🇦
Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, Canada
Effect of Minocycline on Delirium Incidence in Critically Ill Patients
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
- Target Recruit Count
- 160
- Registration Number
- NCT04219735
- Locations
- 🇧🇷
São José Hospital, Criciuma, SC, Brazil
Neuroimmune Dysfunction in Alcohol Use Disorder
- Conditions
- Alcohol DrinkingAlcohol-Related DisordersDiseaseAlcoholismCognitive DysfunctionMinocyclineSubstance-Related DisordersCognition DisorderDrinking BehaviorMental Disorder
- Interventions
- Drug: Sugar pill
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 142
- Registration Number
- NCT04210713
- Locations
- 🇺🇸
Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP), Catonsville, Maryland, United States
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- State University of New York - Downstate Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT04202263
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
Locally Delivered Antibiotics for the Treatment of Periodontitis
- Conditions
- Periodontitis
- Interventions
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Riyadh Elm University
- Target Recruit Count
- 44
- Registration Number
- NCT04125706
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT04104685
- Locations
- 🇺🇸
Foamix Institution #126, Baton Rouge, Louisiana, United States
🇺🇸Foamix Institution #107, Hialeah, Florida, United States
🇺🇸Foamix Institution #132, San Diego, California, United States
Locally Delivered Minocycline in Advanced Periodontitis
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Mahsa University
- Target Recruit Count
- 40
- Registration Number
- NCT04076098
- Locations
- 🇲🇾
MAHSA University, Jenjarum, Selangor, Malaysia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.